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initiation/intensiﬁcation in patients uncontrolled on their current
therapy. RESULTS: The median time to intensiﬁcation of insulin
regimen for T1 patients uncontrolled on premix regimens, was
4.0 years (95% CI 3.2 to 5.4). The median time to initiation of
insulin for T2 patients, prescribed two or more oral agents, with
evidence of poor glycaemic control was 7.0 years (95% CI 6.5
to 7.7). Finally, the median time to intensiﬁcation of the insulin
regimen was 4.2 years (95% CI 3.5 to 6.1) for T2 patients
uncontrolled on a basal regimen and >8 years for those uncon-
trolled on a premix regimen. CONCLUSION: In spite of poor
glycaemic control, insulin-naïve and insulin-treated patients fail
to initiate/intensify insulin therapy for many years. Earlier initi-
ation/intensiﬁcation of insulin therapy is likely to lead to better
control and a reduction in the complications associated with dia-
betes. Barriers to insulin use must be overcome if patients are to
achieve appropriate control.
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OBJECTIVES: As part of the submission to NICE, we evaluated
the cost-effectiveness of inhaled insulin (INH) in patients with
type 1 diabetes uncontrolled on a premix regimen (T1), and
patients with type 2 diabetes uncontrolled on oral anti-diabetic
drugs (T2). METHODS: Using the perspective of the National
Health Service (NHS), a validated Markov model (EAGLE) was
used to estimate the incremental costs and QALYs gained of: 1)
a basal bolus regimen involving INH versus an injected basal
bolus regimen in T1; and 2) a bolus of INH versus i) an injected
basal regimen and ii) an injected premix regimen in T2. The
model simulates the progression of diabetes in 1000 patients over
a time frame of 20 years. A large UK dataset was used to docu-
ment the patients’ clinical characteristics. NHS reference costs
were used as a source for medical costs. Utility/disutility data
were collected in published studies and clinical trial data were
used to document the efﬁcacy of therapies. An annual 3.5% dis-
count rate was used for both costs and outcomes. Probabilistic
sensitivity analysis was performed. RESULTS: In T1 the total
incremental costs (IC) were ≤202,746 and the total QALYs
gained (IE) were 24, leading to a mean incremental cost-effec-
tiveness ratio (ICER) of ≤8510/QALY. In T2, the mean lCER
versus basal was ≤24,285/QALY with IC of ≤497,749 and IE of
21. The mean ICER versus premix was ≤24,555/QALY with IC
of ≤503,185 and IE of 21. The probabilistic sensitivity analysis
showed that for a willingness to pay of ≤30,000 per QALY
gained, INH was cost-effective in 100% of the T1 simulations
and in 92 to 95% of T2 simulations. CONCLUSION: INH is a
cost-effective therapy for T1 and T2 patients uncontrolled on
their current therapy in the UK setting.
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OBJECTIVES: The objective of the study was to translate and
linguistically validate the Satisfaction with Oral Anti-Diabetic
Agents (SOADA) questionnaire for use in 11 countries. The
questionnaire was developed in the United States in 2005 in
order to assess satisfaction with oral anti-diabetic medication in
patients with type 2 diabetes. METHODS: The accepted stan-
dard methodology was used: 2 forward translations, reconcilia-
tion, 2 back translations, back translation review, developer
review, harmonisation meeting, linguistic validation interviews
with 5 or 6 patients with type 2 diabetes and 2 proof readings.
A universal approach was used for French and Spanish with the
aim of developing a single Spanish and a single French version.
RESULTS: While the majority of wording was easily agreed
upon, certain words and phrases were more troublesome. Issues
and solutions included: The ﬁrst French suggestion, “medica-
ment,” did not take into account the possibility of more than
one medication. The ﬁnal agreement was on “medicament(s).”
“Extremely [satisﬁed]” cannot be translated literally in Mexico
as it is too formal. “Muy satisfecho” was selected as the best
alternative for Mexico and Spain. “How quickly” was misun-
derstood in pilot testing in Korea so this was changed to a more
idiomatic “the ‘fastness’.” “Tolerabilidad,” the original Spanish
translation, was found to be problematic during cognitive
debrieﬁng interviews and a simpler alternative was found. The
universal approach produced a single ﬁnal version for French
and Canadian French and very similar ﬁnal translations for
Spanish (for Spain) and Mexican Spanish. CONCLUSIONS: The
SOADA has been translated and linguistically validated and is
now available for use in 11 countries. The universal approach
used for Spanish and French was successful. A number of cul-
tural and linguistic issues became apparent and were resolved.
The measure is now appropriate for use in multinational trials.
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OBJECTIVES: Two patient self-report questionnaires were
developed for use by physicians. They were intended to assess
why diabetic patients were reluctant to switch their treatment
from oral hypoglycaemic agents to insulin or to step up their
insulin dosage when already treated with insulin. This study pre-
sents scores and psychometric validation for both questionnaires.
METHODS: Patients treated with oral hypoglycaemic agents (n
= 1582) and patients already treated with insulin (n = 1296) com-
pleted the questionnaire at baseline, Month 3 and Month 6. Psy-
chometric properties were assessed: 1) structural analysis by
Principal Component Analysis (PCA) with varimax rotation; 2)
internal consistency reliability determination (Cronbach’s alpha);
and 3) concurrent validation (Spearman correlation coefﬁcients
with the Fear of Self-Injecting (FSI) score of the Diabetes Fear of
Injecting and Self-testing Questionnaire (D-FISQ). The ability of
scores to predict the switch to an insulin treatment and increased
numbers of injections at the end of baseline visit was established
by calculating the Area Under the ROC Curve (AUC). RESULTS:
PCA analysis conﬁrmed the ﬁnal questionnaire structure of 14
items grouped into 3 dimensions (Acceptance/Motivation (AM),
Insulin treatment: fear and constraints (FC), and Reluctance to
be injected (RI)). Internal consistency reliability (Cronbach’s
alpha ranging from 0.74 to 0.82) and concurrent validity (FIS
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correlations of 0.41 for FC and 0.42 for RI) were good to excel-
lent. The three scores were predictive of the unwillingness to be
treated with insulin and to step up insulin treatment (AUC
ranging from 0.65 to 0.87). The AM score was predictive of the
switch to an insulin treatment and increased numbers of injec-
tions at the end of baseline visit (AUC of 0.80 and 0.66). CON-
CLUSION: The questionnaires are reliable, valid and a help for
physicians in assessing the hurdles faced by diabetic patients
starting or stepping up insulin treatments.
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OBJECTIVES: To evaluate the patterns and predictors of adher-
ence to statin therapy in all patients with diabetes in the com-
munity. METHODS: We retrospectively studied patients with
type 1 and type 2 diabetes who were resident in Tayside, Scot-
land from 1st January 1993 to 31st May 2003, with at least 6
months of prescriptions of statins. The main outcome measure
was an adherence index. The inﬂuence of several covariates
including age, sex, duration of diabetes, adherence to diabetes
medication and co-morbidities were also assessed. RESULTS: A
total of 5010 patients were included in the study: 4816 with type
2 diabetes and 194 with type 1 diabetes. Median statin adher-
ence was 75% and 77% in type 1 and 2 diabetes respectively,
with a similar distribution in both groups. There were 35% of
type 1’s and 42% of type 2’s with adequate adherence (°Y´80%).
Predictors of adequate adherence in type 2 diabetes were being
older, being an ex-smoker compared to never having smoked,
better adherence to diabetic medication, a lower HbA1c level,
shorter duration of statin therapy, a history of coronary heart
disease, a history of stroke and being prescribed concurrent med-
ication for cardiovascular disease. Conversely, patients pre-
scribed concurrent asthma medication were less adherent to their
statin medication. In type 1 diabetes signiﬁcant predictors were
better adherence to diabetic medication, a lower HbA1c level,
being female and being prescribed concurrent medication for car-
diovascular disease. CONCLUSIONS: Approximately 65% of
type 1 patients and 58% of type 2 patient collected less than
80% of their medically recommended dose of statins. Given 
the increased risk of coronary heart disease facing patients with
diabetes this poor adherence could have signiﬁcant health 
implications.
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OBJECTIVES: Conversion of type 2 diabetic patients previously
treated with a conventional insulin regiment treatment to a com-
bined oral treatment with pioglitazone and glimepiride has been
shown to improve resistance and not to result in an overall dete-
rioration of metabolic control. Thus this study was performed
to evaluate the impact of this conversion on patients’ quality of
life. METHODS: A sample of 116 type 2 diabetic patients (73
men, 43 women; age (mean ± SD) 59.43 ± 9.3 years) were con-
verted as aforementioned. Quality of life was measured by using
the EQ-5D questionnaire (consisting of a ﬁve-question-survey
and the Visual Analogue Scale) and the disease-speciﬁc QSD-R
questionnaire, both at baseline and after six months. Based on
statistical analyses (descriptive statistics, paired t-test, multivari-
ate linear regression model) factors inﬂuencing quality of life
scores were identiﬁed. RESULTS: Overall high quality of life
levels at baseline as well as after six month were measured.
Despite these positive results both questionnaires identiﬁed prob-
lems in the dimensions “pain/ discomfort”/ “physical com-
plaints” and “anxiety/ depression”. The mean EQ-5D index
score (based on German societal perspective) increased from
84.82 to 85.66 (p = 0.660), whereas the mean EQ-VAS score
(patient perspective) increased from 70.72 to 72.88 (p = 0.235).
Mean QSD-R score improved from a global stress score of 0.76
at baseline to 0.70 six months later (p = 0.223). Research results
presented improvements in all dimensions measured. Multiple
regression analysis as well as a subgroup-analysis demonstrated
that a decreasing BMI, a lower duration of disease and male
gender have a positive effect on quality of life. CONCLUSIONS:
The mean quality of life scores did not change signiﬁcantly. The
conversion from insulin to a combined oral treatment with
pioglitazone and glimepiride is possible without deterioration of
health related quality of life.
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OBJECTIVES: To describe the health-related quality of life
(QoL) of type 2 diabetics by age group, duration of disease,
comorbidities and complications, therapeutic interventions and
HbA1c status. METHODS: DETECT (“Diabetes Cardiovascu-
lar Risk-Evaluation: Targets and Essential Data for Commitment
of Treatment”; http://www.detect-studie.de) is a large-scale,
nationally representative, cross-sectional clinical-epidemiological
study with a prospective-longitudinal component in primary
care. Based on a randomised sample of 3188 physicians, the
health state of 55,519 patients was assessed in a standardised
way in 2003. Frequency of problems in the EQ-5D items mobil-
ity, self-care, usual activities, pain/discomfort and anxiety/
depression as well as the additive total score were analysed in n
= 6558 type 2 diabetics. RESULTS: The most frequent QoL
restrictions were in the domains of pain/discomfort (74.1%) and
mobility (44.3%) followed by daily activities (34.1%),
anxiety/depression (31.4%) and self-care (17.2%). The mean
additive total score was 68.1. That was, after adjustment for age
and gender, signiﬁcantly lower than in nondiabetics (72.4) or in
healthy attendees (81.7). Overall and in each QoL domain, prob-
lems increased if micro- and macrovascular disease was present,
and with the age of patients or duration of diabetes respectively.
There were no signiﬁcant differences between patients with or
without therapy (diet, exercise and oral antidiabetics). However,
patients with insulin and combined therapy had considerably
lower Qol scores, even after adjustment for age, gender, dura-
tion of diabetes and presence of micro- and macro-vascular
disease. HbA1c adjustment had only small effects on the EQ-5D
dimensions. Compared to patients with optimal HbA1c values
(<6%), poorly adjusted patients (HbA1c > 8%) reported signif-
icantly more problems at the dimensions mobility and self-care.
CONCLUSIONS: Our data provide, in unprecedented detail, the
health related QoL of type 2 diabetics in German primary care,
highlighting the association of insulin and combined treatments
with reduced QoL.
